Business Wire

THE-BRIJ

19.12.2022 12:53:36 CET | Business Wire | Press release

Share
Introducing THE BRIJ - A World of Arts and Culture

Serendipity Arts today announced its vision to bring the arts to life through a cutting-edge arts and culture centre, that will be a bridge that connects the world to the arts, and its transformational power. THE BRIJ will dedicate space, time, and resources to create ground-breaking art that is transformational and meaningful. Through this centre, Serendipity Arts also hopes to spark conversations around the arts across the South Asian region worldwide, assimilating regional flavours, traditions, and cultures, while also building a sustainable artistic ecosystem. The upcoming institution is named after and pays homage to late Mr. Brijmohan Lall Munjal, Indian industrialist and visionary, Mr. Sunil Kant Munjal’s father.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221218005083/en/

Outlining the idea behind THE BRIJ, Mr. Sunil Kant Munjal, Founder & Patron of Serendipity Arts and Founder of THE BRIJ, said, “Our privileges always come with responsibility; this initiative is a responsibility and a passion project for us. THE BRIJ stems from a responsibility we feel towards the arts; the way art is seen today, compared to how it was perceived in the region, prior to colonization. In terms of its programming, THE BRIJ will retain the aura of the flagship festival while adding multiple layers of practice, learning and experimentation to its programs, around the year. Planned around diverse creative practices, the facility will have higher arts education, incubation labs, centres of cultural innovation, performance spaces, and museums at a never-before-seen scale, in an interdisciplinary manner. In effect it will be the complete ecosystem for Arts & Culture at one place.”

The three essential elements of the Centre will be Education & Research, Multidisciplinary Experiences and Innovation & Incubation with training, workshops, and residencies. The one-of-its-kind centre is currently under construction and will have a Museum, an Academy & Workshop, a Gallery, Library, a Stepwell Gallery, an Arena, Theatre and Black Box, and much more. The facility will also house a crafts centre and an artisanal village, where dying and fringe art & craft forms will be brought back to life, through research, practice, and incubation. The entire campus has been designed in a way that it is 100 percent accessible to the differently abled.

With interdisciplinarity, education, and intergenerational exchange as its key purposes, THE BRIJ will emphasise excellence, change, innovation, equality, integrity, and responsibility. The aim is to gift the city of Delhi and the nation a cultural centre, enabling visitors with a shared passion and curiosity for the arts to cherish and immerse in it, inclusively. The centre hopes to create a space that attracts academics, intellectuals, students, art lovers, critics, artists, and members of the public, who can come together to create a bustling creative community.

With cutting-edge technologies that promise to bring forth unique and engaging experiences for visitors, THE BRIJ will be truly global in form and spirit. It will have all the ingredients for an inclusive and immersive experience with assisted navigation and omnichannel availability, while also driving the imperatives of sustainability through a reduced carbon footprint. At the same time, an efficient operational backend, a robust infrastructure for security and connectivity, and futuristic technologies will support the museum and the dream.

Speaking about THE BRIJ, Ms Smriti Rajgarhia, Director, Serendipity Arts Foundation and Festival, said, “THE BRIJ is our endeavour to strengthen India’s place in the global cultural dialogue and make international art accessible to the discerning and the common enthusiast. We aim to contribute to the cultural quotient of the region, through restored artworks and revival of lost or at-risk art forms, while also seeking to redefine the future of arts through interdisciplinary collaboration and innovation.”

Among the many features that make this cultural centre unique are the twin driving forces of economy and sustainability, both of which find expression through this building. THE BRIJ will also aim to meet the Foundation’s aspiration to emerge as a catalyst for change, by creating employment opportunities, contributing to India’s and New Delhi’s cultural economy and attracting both Indian and international tourists. Courtesy of Serendipity Arts, THE BRIJ already has and will further enhance its partnerships and exchanges with global institution and creative organizations, to build a facility with state-of-the-art infrastructure, that is organic and future facing.

The entire campus of THE BRIJ would have a platinum rating for green buildings and will generate more than 5200 direct and indirect employment. Besides, more than 120,000 people are expected to benefit from the education and skilling programmes that will be made available. About 90,000 young learners will have free access to the museum, with over 200 art start-ups and projects supported through the incubation centre. Through its multilateral and multicultural platform, the one-of-its-kind Museum hopes to significantly contribute to India’s GDP.

Speaking on the initiative, key member of our expert panel of architects, Mr. Dikshu Kukreja, Managing Principal, CP Kukreja Architects (CPKA), New Delhi, said, “The design philosophy for THE BRIJ is to create a co-existential architecture where the building and landscape dissolve into one. The architecture amplifies its context with buildings envisioned as magnified rock outcrops just like the quartzite rock formations found on the site. The design allows the adjoining forest to permeate into the site. All this as the vibrant and varied programmatic elements form a musical ensemble experiencing hitherto unexplored and futuristic sustainable design strategies.”

In addition to Mr Sunil Kant Munjal, THE BRIJ is also the dream of patron and social entrepreneur Shefali Munjal, Founder-Patron of THE BRIJ. The Board of Advisors include media personality and the current Chair of the Royal College of Arts, UK, Sir Peter Bazelgette; Harsh Goenka, Chairman of the RPG Group, an ardent collector of art and a strong advocate for fostering innovation; and Deepak Iyer, who heads the Accenture Microsoft Business group for Southeast Asia.

Advisors for THE BRIJ include poet, cultural theorist, and curator Ranjit Hoskote; Manu Chandra, Chef Partner for THE BRIJ and one of the pioneers of the gastropub scene in India; Shubha Mudgal, Padma Shri recipient and winner of the Gold Plaque Award for Special Achievement in Music at the Chicago International Film Festival; Aneesh Pradhan, noted table player; and Anuradha Kapur, recipient of the Sangeet Natak Award for Direction in Theatre and the instrumental figure at the National School of Drama, Delhi and Bangalore.

For more details, visit www.thebrij.world

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221218005083/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye